Vaxil Bio Ltd (VXL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaxil Bio Ltd (VXL) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-28.00K ≈ $-20.25K USD) by net assets (CA$667.00K ≈ $482.50K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vaxil Bio Ltd balance sheet quality to measure how much of total assets are equity-financed.
Vaxil Bio Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Vaxil Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vaxil Bio Ltd (VXL) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Vaxil Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxil Bio Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SkinBioTherapeutics PLC
LSE:SBTX
|
-0.053x |
|
Emmerson PLC
LSE:EML
|
0.000x |
|
Kavango Resources PLC
LSE:KAV
|
-0.160x |
|
GETT Gold Inc
V:GETT
|
-0.004x |
|
International Zeolite Corp
V:IZ
|
-0.053x |
|
FOXO Technologies Inc.
NYSE MKT:FOXO
|
-0.002x |
|
Predator Oil & Gas Holdings Plc
LSE:PRD
|
0.001x |
|
SCRYB INC.
F:EIY
|
N/A |
Annual Cash Flow Conversion Efficiency for Vaxil Bio Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Vaxil Bio Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see VXL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$716.00K ≈ $517.94K |
CA$-240.00K ≈ $-173.61K |
-0.335x | +46.76% |
| 2023-12-31 | CA$891.00K ≈ $644.54K |
CA$-561.00K ≈ $-405.82K |
-0.630x | +2.55% |
| 2022-12-31 | CA$1.14 Million ≈ $821.77K |
CA$-734.00K ≈ $-530.96K |
-0.646x | -1.33% |
| 2021-12-31 | CA$1.70 Million ≈ $1.23 Million |
CA$-1.08 Million ≈ $-784.15K |
-0.638x | +53.52% |
| 2020-12-31 | CA$804.00K ≈ $581.60K |
CA$-1.10 Million ≈ $-797.89K |
-1.372x | -234.20% |
| 2019-12-31 | CA$-583.00K ≈ $-421.73K |
CA$-596.00K ≈ $-431.14K |
1.022x | +147.16% |
| 2018-12-31 | CA$435.00K ≈ $314.67K |
CA$-943.00K ≈ $-682.15K |
-2.168x | -205.47% |
| 2017-12-31 | CA$-487.00K ≈ $-352.29K |
CA$-1.00 Million ≈ $-724.11K |
2.055x | +190.01% |
| 2016-12-31 | CA$656.00K ≈ $474.54K |
CA$-1.50 Million ≈ $-1.08 Million |
-2.284x | -179.41% |
| 2015-12-31 | CA$-217.00K ≈ $-156.97K |
CA$-624.00K ≈ $-451.39K |
2.876x | +176.91% |
| 2014-12-31 | CA$34.48K ≈ $24.94K |
CA$-128.91K ≈ $-93.25K |
-3.739x | -83.25% |
| 2013-12-31 | CA$187.94K ≈ $135.95K |
CA$-383.44K ≈ $-277.37K |
-2.040x | +10.43% |
| 2012-12-31 | CA$72.15K ≈ $52.19K |
CA$-164.34K ≈ $-118.88K |
-2.278x | -31.42% |
| 2011-12-31 | CA$264.09K ≈ $191.04K |
CA$-457.76K ≈ $-331.14K |
-1.733x | -211.04% |
| 2010-12-31 | CA$682.06K ≈ $493.39K |
CA$-380.10K ≈ $-274.96K |
-0.557x | -98.24% |
| 2009-12-31 | CA$515.90K ≈ $373.20K |
CA$-145.03K ≈ $-104.91K |
-0.281x | -- |
About Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.